Startups
Nearly one year after it was launched by Pfizer and Bain Capital, Cerevel Therapeutics has tapped industry veteran Tony Coles as its chief executive officer.
MaRS Innovation is pleased to announce that, on its 10th anniversary, it has changed its name to Toronto Innovation Acceleration Partners to reflect its refined focus on venture building and growth to advance its Members’ health science innovations .
BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy.
At this time, LUCA’s pipeline includes therapies for UTI, preterm birth and bacterial vaginosis.
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Since its launch, Kronos has demonstrated SMM’s potential to identify compounds that bind to target proteins directly or interfere at nanomolar potency with protein activity.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
Arie Belldegrun, founder and former chair, president and chief executive officer of Kite Pharma, has teamed up with real estate developer Tishman Speyer to launch a biotech-focused real estate company, Breakthrough Properties.
MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.
Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech veteran Marcel van der Brug, who is the chief scientific officer for therapeutics.
PRESS RELEASES